Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Celgene Corporation (NASDAQ:CELG) is down about 35 percent year-over-year, and as management resists challenges to critical Revlimid patents, analysts are at odds about where the stock could head from here.
The Ratings
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102.
Argus analyst David Toung downgraded the stock from Buy to Hold.
The Bull Thesis
By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Gal expects a victory in the second half of 2019 or a settlement even earlier.
His bullishness is bolstered by Celgene’s potential to secure four significant, valuation-driving approvals in the next two years or, in the case that valuation remains depressed, to pursue governance or ownership changes.
“This is fundamentally a valuation call on a 'cliff' company,” Gal said in a Wednesday note.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The Bear Thesis
Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.
“We remain concerned about the company’s overreliance on Revlimid (65 percent of revenue) and about setbacks in its product pipeline,” Toung said. “While Celgene has settled one legal challenge to its Revlimid patents, it continues to fight challenges from other potential generic competitors.”
His downgrade also accounts for a perceived drop in financial strength after Celgene took on more debt to fund acquisitions.
Price Action
Celgene shares were up 0.64 percent at $77.10 after the open Wednesday.
Related Links:
Celgene Forges Oncology Partnership With Germany's Evotec
Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.